Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.

被引：0
|
作者：
Kudchadkar, Ragini Reiney [1 ]
Gallenstein, Donna [1 ]
Martinez, Alberto J. [1 ]
Yu, Bin [1 ]
Weber, Jeffrey S. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8582
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [2] Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.
    Agrawal, Shruti
    Feng, Yan
    Kollia, Georgia
    Saeger, Sally
    Ullmann, Martin
    McDonald, Dan
    Gupta, Ashok Kumar
    Roy, Amit
    Masson, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).
    Hodi, F. Stephen
    Sznol, Mario
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Wigginton, Jon
    McDonald, Dan
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
    Wang, Changyu
    Thudium, Kent B.
    Han, Minhua
    Wang, Xi-Tao
    Huang, Haichun
    Feingersh, Diane
    Garcia, Candy
    Wu, Yi
    Kuhne, Michelle
    Srinivasan, Mohan
    Singh, Sujata
    Wong, Susan
    Garner, Neysa
    Leblanc, Heidi
    Bunch, R. Todd
    Blanset, Diann
    Selby, Mark J.
    Korman, Alan J.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (09) : 846 - 856
  • [5] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC)
    McDermott, David F.
    Drake, Charles G.
    Sznol, Mario
    Choueiri, Toni K.
    Powderly, John
    Smith, David C.
    Wigginton, Jon
    McDonald, Dan
    Kollia, Georgia
    Gupta, Ashok Kumar
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [7] Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
    Hodi, F. Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
    Callahan, Margaret K.
    Horak, Christine E.
    Curran, Michael A.
    Hollman, Travis
    Schaer, David A.
    Yuan, Jianda
    Lesokhin, Alexander M.
    Kitano, Shigehisa
    Hong, Quan
    Ariyan, Charlotte Eielson
    Busam, Klaus J.
    Feely, William
    Jure-Kunkel, Maria
    Grosso, Joseph
    Simon, Jason S.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
    Hodi, Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne L.
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William H.
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert A.
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok
    Sosman, Jeffrey A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177
  • [10] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
12345